SCHEMBL26686172

SCHEMBL26686172

Nc1n[nH]c2ccc(-c3ccnc4[nH]c(CCCN5CCOCC5)cc34)cc12

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 4/20 0.51
▸ CCNK O75909 2/20 0.44
▸ CDK12 Q9NYV4 2/20 0.44
▸ WNT1 P04628 2/20 0.43
▸ DYRK1A Q13627 2/20 0.43
▸ AURKA O14965 1/20 0.42
▸ AURKB Q96GD4 1/20 0.42
▸ MAPK8 P45983 6/20 0.41
▸ CAMKK2 Q96RR4 6/20 0.41
▸ CHUK O15111 5/20 0.41
▸ INSR P06213 4/20 0.41
▸ GSK3B P49841 1/20 0.41
▸ KCNH2 Q12809 1/20 0.41
▸ TBK1 Q9UHD2 2/20 0.41
▸ ACVR1 Q04771 1/20 0.41
▸ NEK1 Q96PY6 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26686058 0.94 JAK2 (0.53) JAK2CCNKCDK12WNT1DYRK1A
SCHEMBL26686672 0.91 DYRK1A (0.42) JAK2CCNKCDK12WNT1DYRK1A
SCHEMBL26686381 0.89 JAK2 (0.60) JAK2CCNKCDK12WNT1DYRK1A
SCHEMBL26685962 0.85 DYRK1A (0.43) JAK2CCNKCDK12WNT1DYRK1A
SCHEMBL31240548 0.85 TBK1 (0.46) JAK2WNT1DYRK1AMAPK8CAMKK2
SCHEMBL26685942 0.80 CCNK (0.55) JAK2CCNKCDK12DYRK1AAURKA
SCHEMBL31240247 0.80 JAK2 (0.67) JAK2AURKAAURKBMAPK8CAMKK2
SCHEMBL31240333 0.79 JAK2 (0.46) JAK2WNT1DYRK1AMAPK8CAMKK2
SCHEMBL26685993 0.79 GSK3B (0.44) JAK2DYRK1AGSK3BKCNH2TBK1
SCHEMBL26686734 0.79 CCNK (0.44) JAK2CCNKCDK12AURKAAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4705291-A1 IKK-ALPHA INHIBITORS Cancer Research Technology Limited (GB) 2026-03-11 — — EP claimed
US-20250304576-A1 IKK INHIBITORS CANCER RESEARCH TECH LTD (GB) 2025-10-02 — — US claimed
EP-4522597-A1 IKK INHIBITORS Cancer Research Technology Limited (GB) 2025-03-19 — — EP claimed
CN-119562945-A IKK inhibitors 癌症研究技术有限公司 2025-03-04 — — CN claimed
WO-2024228035-A1 IKK-ALPHA INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2024-11-07 — — WO claimed
WO-2023218201-A1 IKK INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-11-16 — — WO claimed
EP-4705291-A1 IKK-ALPHA INHIBITORS Cancer Research Technology Limited (GB) 2026-03-11 — — EP disclosed
US-20250304576-A1 IKK INHIBITORS CANCER RESEARCH TECH LTD (GB) 2025-10-02 — — US disclosed
EP-4522597-A1 IKK INHIBITORS Cancer Research Technology Limited (GB) 2025-03-19 — — EP disclosed
CN-119562945-A IKK inhibitors 癌症研究技术有限公司 2025-03-04 — — CN disclosed
WO-2024228035-A1 IKK-ALPHA INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2024-11-07 — — WO disclosed
WO-2023218201-A1 IKK INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-11-16 — — WO disclosed
WO-2023218201-A1 IKK INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-11-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304576-A1 IKK INHIBITORS NFKBIA, IKBKE, IKBKB JAK2 207/4885CCNK 222/4885CDK12 171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback